Genmab Takes On Big Commercial Challenge With Merus Buyout

 
• By Andrew McConaghie
  
Jan van de Winkel
CEO Jan van de Winkel is overseeing Genmab's transition away from reliance on royalty revenue - but this brings new clinical and commercial challenges. • Source: Genmab

More from Clinical Trials

More from R&D